scholarly journals Pharmaceutical Preparation and Standardization of Swarna Vanga and Its Clinical Efficacy as Adjuvant to Reduce Adverse Effects of Chemotherapy with Special Reference to Its Rasayana Property

Author(s):  
Dr. Dhanashree Ghotkar

Abstract: Cancer is most dreadful disease affecting mankind. Many innovative healing modalities and hundreds of cancer treatments have resulted from extensive research. With chemotherapy and radiotherapy, surgical excision is the oldest and most tested method. This leads to therapy problems, poor health, and a decline in quality of life, all of which necessitate treatment discontinuation. Anorexia, diarrhoea, nausea, vomiting, and mucositis can all be caused by psychological causes. The anorexiacachexia syndrome is the most common cause of death among cancer patients. Cancer cachexia is characterised by metabolic, hormonal, and cytokine abnormalities that lead to progressive wasting. Swarna Vanga is a Kupipakwa Rasayana mentioned in Rasatarangini. Chemically it is stannous sulphide containing Shuddha Parad, Shuddha Vanga, Shuddha Gandhak, Shuddha Navasadar. Till today, no study has been carried out using Swarna Vanga for its Rasayana and Balya properties. Hence an attempt was given to study the pharmaceutical preparation, standardization and clinical efficacy of the drug in reducing adverse effects of chemotherapy with special reference to its Rasayana property through this dissertation. Thus the present study entitled “Pharmaceutical preparation and standardization of Swarna Vanga and its clinical efficacy as adjuvant to reduce adverse effects of chemotherapy with special reference to its Rasayana property” was carried out. Keywords: Swarna Vanga, adjuvant, Rasayana, cancer, chemotherapy, adverse effects, standardization.

2021 ◽  
Vol 28 (3) ◽  
pp. 2007-2013
Author(s):  
Guido V. Schiappacasse

The COVID-19 situation is a worldwide health emergency with strong implications in clinical oncology. In this viewpoint, we address two crucial dilemmas from the ethical dimension: (1) Is it ethical to postpone or suspend cancer treatments which offer a statistically significant benefit in quality of life and survival in cancer patients during this time of pandemic?; (2) Should we vaccinate cancer patients against COVID-19 if scientific studies have not included this subgroup of patients? Regarding the first question, the best available evidence applied to the ethical principles of Beauchamp and Childress shows that treatments (such as chemotherapy) with clinical benefit are fair and beneficial. Indeed, the suspension or delay of such treatments should be considered malefic. Regarding the second question, applying the doctrine of double-effect, we show that the potential beneficial effect of vaccines in the population with cancer (or those one that has had cancer) is much higher than the potential adverse effects of these vaccines. In addition, there is no better and less harmful known solution.


Author(s):  
Pasquale F. Innominato ◽  
David Spiegel

The circadian timing system temporally regulates biological functions relevant for psycho-physical wellbeing, spanning all the systems related to health. Hence, disruption of circadian rhythms, along with sleep cycles, is associated with the development of several diseases, including cancer. Moreover, altered circadian and sleep functions negatively impact on cancer patients’ quality of life and survival, above and beyond known determinants of outcome. This alteration can occur as a consequence of cancer, but also of anti-cancer treatments. Indeed, circadian rhythms govern also the ability of detoxifying chemotherapy agents across the 24 hours. Hence, adapting chemotherapy delivery to the molecular oscillations in relevant drug pathways can decrease toxicity to healthy cells, while increasing the number of cancer cells killing. This chronomodulated chemotherapy approach, together with the maintenance of proper circadian function throughtout the whole disease challenge, would finally result in safer and more active anticancer treatments, and in patients experiencing better quality and quantity of life.


1997 ◽  
Vol 4 (5) ◽  
pp. 407-412
Author(s):  
Donna Corwin Moss

Background Support groups help their participants to cope with the emotional and practical impact of their illnesses. Methods The effectiveness of the Leukemia Society of America support groups in enhancing the quality of life for their participants is reviewed. The groundwork, purpose, and structure of such groups, as well as alternate sources of support, are presented. Evaluation and future directions for oncology groupwork are discussed. Results Support groups complement the therapies provided by clinical practitioners and scientists by addressing the additional needs of cancer patients over the course of illness and survival. Conclusions New concepts and methods that address the needs of specific age-groups and incorporate the newly generated data on cancer treatments will further enhance the benefits provided by support groups.


2020 ◽  
Vol 30 (Supplement_5) ◽  
Author(s):  
K Apostolidis

Abstract The speaker will present the perspective of the cancer patients, and the challenges they encounter across the spectrum of care and what measures they consider relevant in terms of prevention, diagnosis, treatment and, indeed, to raise awareness of the impact of AMR on rendering cancer treatments ineffective. She will elaborate on survivorship, and on the impact of AMR on the quality of life of patients, their carers, and families. Emphasis will be given on the implications of modern therapies, such as immunotherapy, representing a unique challenge in terms of better understanding the effect on overall health of patients, with the effect they have the immune system, further weakening the patient and leaving him/her exposed to infections potentially of higher risk than cancer itself.


Medicina ◽  
2021 ◽  
Vol 57 (7) ◽  
pp. 730
Author(s):  
Jeong Won Lee ◽  
Ki Ho Seol

Keloids are a benign fibroproliferative disease with a high tendency of recurrence. Keloids cause functional impairment, disfigurement, pruritus, and low quality of life. Many therapeutic options have been used for keloids. However, the high recurrence rates have led to the use of adjuvant therapy after surgical keloid excision. There are different radiotherapy regimens available, and the advantages and disadvantages of each are still unclear. The aim of this review is to explain the appropriate radiotherapy regimen for keloids as well as discuss the recent reports on keloid management with radiotherapy. Adjuvant radiotherapy after surgical excision for keloids yields excellent local control with tolerable side effects. Hypofractionated radiotherapy with a BED of more than 28 Gy (α/β value of 10) after excision is recommended in the light of its biologic background.


2005 ◽  
Vol 14 (4) ◽  
pp. 320-328 ◽  
Author(s):  
C. Lundh Hagelin ◽  
Åke Seiger ◽  
C. J. Fürst

2010 ◽  
Vol 46 (4) ◽  
pp. 617-632 ◽  
Author(s):  
André de Oliveira Baldoni ◽  
Farah Maria Drumond Chequer ◽  
Elisa Raquel Anastácio Ferraz ◽  
Danielle Palma de Oliveira ◽  
Leonardo Régis Leira Pereira ◽  
...  

In recent decades, the world has undergone a demographic transformation with a rapid growth of the elderly population, resulting in an increased demand for funds to maintain their health and drug consumption. Pharmacokinetic and pharmacodynamic changes occurring in the elderly can interfere directly in the adverse effects of drugs and increase the risk of intoxication. In addition, there are external factors interfering with the pharmacotherapy of the elderly, such as inappropriate use and the lack of access to information. Many therapeutic classes of drugs should be used with caution or avoided in the elderly population, such as anti-inflammatory and some anti-hypertensive drugs, diuretics and digitalis. If not managed carefully, these medicines can affect the safety and quality of life in the elderly. Thus, the aim of this review was to identify drugs that should be used with caution in elderly patients in order to avoid intoxication and/or adverse drug events.


Sign in / Sign up

Export Citation Format

Share Document